Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Products under Development by Stage of Development | 8 | 1 |
| RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Products under Development by Therapy Area | 9 | 1 |
| RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Products under Development by Indication | 10 | 1 |
| RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Products under Development by Companies | 13 | 2 |
| RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Therapeutics Assessment | 15 | 6 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Companies Involved in Therapeutics Development | 21 | 9 |
| Basilea Pharmaceutica AG | 21 | 1 |
| Eli Lilly and Company | 22 | 1 |
| F. Hoffmann-La Roche Ltd. | 23 | 1 |
| Hanmi Pharmaceuticals, Co. Ltd. | 24 | 1 |
| Millennium Pharmaceuticals, Inc. | 25 | 1 |
| Novartis AG | 26 | 1 |
| Redx Pharma Plc | 27 | 1 |
| Sirnaomics, Inc. | 28 | 1 |
| VG Life Sciences, Inc. | 29 | 1 |
| RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Drug Profiles | 30 | 15 |
| BAL-3833 Drug Profile | 30 | 2 |
| HM-95573 Drug Profile | 32 | 1 |
| hydroxychloroquine + sorafenib tosylate Drug Profile | 33 | 2 |
| LXH-254 Drug Profile | 35 | 1 |
| LY-3009120 Drug Profile | 36 | 2 |
| RG-7304 Drug Profile | 38 | 1 |
| Small Molecules to Inhibit Pan-RAF Kinase for Oncology Drug Profile | 39 | 1 |
| Small Molecules to Inhibit Pan-Raf Kinases for Colorectal Cancer Drug Profile | 40 | 1 |
| STP-503 Drug Profile | 41 | 1 |
| TAK-580 Drug Profile | 42 | 2 |
| TEW-0201 Drug Profile | 44 | 1 |
| RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Dormant Projects | 45 | 2 |
| RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Discontinued Products | 47 | 1 |
| RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Featured News &Press Releases | 48 | 11 |
| Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting | 48 | 1 |
| Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting | 48 | 1 |
| Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent | 49 | 1 |
| Apr 22, 2015: Deciphera Pharmaceuticals Presents Data Highlighting pan-RAF inhibitor Cetuximab including Proprietary and Partnered Programs at AACR 2015 Annual Meeting | 49 | 1 |
| Apr 20, 2015: Lilly Releases Early-Stage Pipeline Data On LY3009120 at AACR Annual Meeting 2015 | 50 | 1 |
| Nov 10, 2014: Hanmi To Initiate A Phase 1 Clinical Trial Of HM95573, The Next Generation Targeted Therapy For Melanoma Treatment | 51 | 1 |
| Sep 04, 2014: VG Life Sciences Progress Update Phase I Cancer Study | 51 | 1 |
| Apr 07, 2014: Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for LY3009120 | 52 | 1 |
| Mar 14, 2014: VG Life Sciences's Reports on Clinical Outcomes in Phase I Cancer Study | 53 | 1 |
| Dec 13, 2013: VG Life Sciences Update on Phase I Cancer Study | 53 | 1 |
| Jul 25, 2013: VG Life Sciences Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association; | 54 | 1 |
| Apr 04, 2013: VG Life Sciences Reports Positive Safety Results Of Hydroxychloroquine And Sorafenib Combination Therapy In Second Cohort Of Phase I Solid Tumor Study | 55 | 1 |
| Jan 31, 2013: VG Life Sciences Reports Positive Results From Phase I Ovarian Cancer Trial Using Sorafenib Combined With Hydroxychloroquine | 55 | 1 |
| Jan 14, 2013: VG Life Sciences Receives IRB Approval To Expand Phase I Cancer Trial Of Hydroxychloroquine In Combination With Sorafenib | 56 | 1 |
| Jul 19, 2012: Viral Genetics Begins Phase I Clinical Trial For Ovarian Cancer | 57 | 2 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |